In brief: CASI Pharmaceuticals launches first product in China

Bavarian Nordic acquire pair of commercial vaccines from GSK
Credit: Lemau Studio

CASI Pharmaceuticals is launching its first commercial product in China via partner Ligand Pharmaceuticals.

The company will launch melphalan hydrochloride for injection (Evomela), which uses Ligand’s Captisol technology in its formation.

Evomela received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

It is the only approved melphalan product available in China.